Stephens lowered the firm’s price target on Ingredion (INGR) to $150 from $155 and keeps an Equal Weight rating on the shares ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...